Inavolisib drug-drug interaction analysis

In clinical applications, drug-drug interactions are a problem that cannot be ignored, especially for patients undergoing long-term treatment. Drug interactions may affect the therapeutic effect or increase adverse reactions. Inavolisib (Inavolisib), as a PI3Kα inhibitor, may interact with other drugs through multiple pathways, including inhibition of drug metabolizing enzymes, competitive binding of drugs, and the effects of drugs on other targets.

First of all, the metabolism of inaliset mainly depends onCYP3A4 enzyme. Therefore, any drug that can affect CYP3A4 activity may interact with inaliset. For example, strong CYP3A4 inhibitors such as clarithromycin, itraconazole, etc. may lead to an increase in the plasma concentration of inariside, thereby increasing its risk of toxicity. When using these drugs, patients should adjust the dosage or choose other alternative treatments under the guidance of their doctor.

On the other hand,CYP3A4 inducers (such as phenobarbital, rifampicin) may accelerate the metabolism of inalised, thereby reducing its plasma concentration and reducing the therapeutic effect. Therefore, during treatment, if patients need to use CYP3A4 inducers, the treatment effect should be closely monitored and the dose of inaliset should be adjusted if necessary.

In addition, inalise may interact with some anticoagulant drugs, antihypertensive drugs, etc. For example, when inalised is used together with anticoagulant drugs such as warfarin, it may affect coagulation function, and coagulation function needs to be monitored during use to avoid an increase in the risk of bleeding. Similarly, concomitant use of inaliset with certain antihypertensive agents may affect blood pressure control, requiring dose adjustment or increased frequency of monitoring.

Inalise may also have synergistic effects with other anti-cancer drugs, such asCDK4/6 inhibitors, hormone drugs, etc., to enhance the anti-tumor effect. When used in combination, a reasonable combination needs to be made based on the specific conditions of breast cancer patients and the interaction characteristics of the drugs to improve the therapeutic effect and reduce adverse reactions.

Reference materials:https://en.wikipedia.org/wiki/Inavolisib